Workflow
Maravai LifeSciences(MRVI) - 2025 Q2 - Quarterly Results

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings "Our base revenue, which excludes revenue from high-volume CleanCap, grew 5% in the quarter, led by strong demand for our Cygnus products and services," said Bernd Brust, CEO, Maravai LifeSciences. Brust continued, "While we are encouraged by the base business growth, our existing cost struct ...